Overexpression of GRK6 attenuates neuropathic pain via suppression of CXCR2 in rat dorsal root ganglion

Yuan Zhou, MD1,2,*, Rong-Ji Li, MS1,*, Meng Li, BS1, Xuelian Liu, BS1, Hong-Yan Zhu, MS3, Zhong Ju, BS1, Xiuhua Miao, MD3 and Guang-Yin Xu, MD, PhD1,3

Abstract

G protein-coupled kinase (GRK) 6 is a member of the GRK family that mediates agonist-induced desensitization and signaling of G protein-coupled receptors (GPCRs), thus involving in a wide variety of processes including inflammation and nociception. Recent studies have indicated that chemokines play an important role in chronic pain via increased expression of respective GPCRs. This study was designed to investigate the role of GRK6 and its interaction with substrate chemokine receptors in dorsal root ganglion (DRG) in a rat model of neuropathic pain induced by chronic constriction injury (CCI). Following induction of CCI, GRK6 expression was significantly downregulated in rat DRGs at L4-L6 segments. Overexpression of GRK6 using lentiviral-mediated production strategy via sciatic nerve injection markedly attenuated mechanical allodynia and thermal hyperalgesia in CCI rats. Overexpression of GRK6 also drastically reversed the hyperexcitability of DRG neurons innervating the hind paw and suppressed the enhanced expression of CXCR2 in DRGs of CCI rats. In addition, co-immunoprecipitation, immunofluorescence, and correlation analysis supported the interaction between GRK6 and CXCR2. These results suggest that GRK6 might be a key molecular involved in peripheral mechanism of neuropathic pain and that overexpression of GRK6 might be a potential strategy for treatment for neuropathic pain through inhibition of CXCR2 signal pathway.

Keywords

Neuropathic pain, dorsal root ganglion, GRK6, CXCR2

Date received: 19 January 2016; revised: 23 March 2016; accepted: 29 March 2016

Introduction

Neuropathic pain is one of the most severe types of chronic pain in which the involved mechanisms remain largely unknown and clinical treatment options are very limited, thus debilitating millions of people worldwide and imposing a heavy burden on the society. It is generally accepted that neuropathic pain is an expression of neural plasticity, which occur in both primary sensory neurons (peripheral sensitization) and CNS neurons, such as spinal cord dorsal horn and cortical neurons (central sensitization). Neuroinflammation has been thought to play a pivotal role in the pathogenesis of neuropathic pain.1 Increased excitability of sensory neurons after exposure to inflammatory mediators including cytokines and chemokines contributes to the enhanced pain sensitivity.2 The intracellular mechanisms of the increased neuronal excitability are thought to include alterations

1Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psycho-Diseases, Institute of Neuroscience, Soochow University, Suzhou, PR. China
2Department of Anesthesiology, Affiliated Hospital of Nantong University, Nantong, PR. China
3Center for Translational Medicine, Affiliated Zhangjiagang Hospital of Soochow University, Zhangjiagang, PR. China
*Yuan Zhou and Rong-Ji Li contributed equally to this work.

Corresponding author:
Guang-Yin Xu, Laboratory of Translational Pain Medicine, Institute of Neuroscience, Soochow University, 199 Ren-Ai Road, Suzhou 215123, PR. China.
Email: guangyinxu@suda.edu.cn
in activation levels of several kinases and expression or function of receptors and ion channels.

Merging evidence suggests that abundant mediators are involved in neuropathic pain function via activating G protein-coupled receptors (GPCRs) expressed in sensory neurons. G protein-coupled kinases (GRKs) regulate cellular signaling by promoting desensitization of agonist-occupied GPCRs. GRKs-mediated phosphorylation of the activated GPCR promotes binding of arrestin proteins and rapid uncoupling from the G proteins, leading to GPCR desensitization and internalization. Increasing evidence has shown that intracellular levels of GRK determine GPCR sensitivity. GRKs also interact directly with a variety of downstream signaling molecules, thereby regulating cellular signaling pathways. GRK6, as a ubiquitously expressed member of the GRK family, has been shown to play a critical role in inflammatory diseases. It has been reported that desensitization of many GPCRs, such as CGRP receptors, the BLT1 receptors for the leukotriene LTB4, and the chemokine receptors, are all regulated by GRK6. Several reports have demonstrated the involvement of GRK6 in pain modulation. More recently, we have reported that chronic neuropathic pain is associated with decreased levels of the GRK6 in spinal neurons. But it is largely unknown whether the peripheral GRK6 in dorsal root ganglion (DRG) and which specific substrate GPCR signaling pathway play a role in neuropathic pain.

Chemokines, a family of small secreted cytokines, have been demonstrated to regulate chronic pain via neuroinflammation at different anatomical locations, including nerve, DRGs, spinal cord, and the brain. They are classified in different families according to the number and localization of amino terminal cysteine residues. Of high interest, some members of the CXC chemokine family, with a glutamate–leucine–arginine (ELR+) domain in the amino terminal portion of the molecule, are known notably for their ability to attract neutrophils to the site of inflammation. The representative components of this subfamily, CXCL1 (keratinocyte-derived chemokine, KC; GROα), CXCL8 (interleukin-8, IL-8), and CXCL12, have been revealed an upregulation in several animal models following nerve injury and implicated in the development and maintenance of neuropathic pain. The biological effects of chemokines are mediated via G protein-coupled chemokine receptors, including CXCR1, CXCR2, and CXCR4. Compelling evidence demonstrated that expression of these chemokine receptors is significantly upregulated during both early-phase and late-phase of chronic pain and that blocking these receptors can reverse pain-related behaviors. However, the possible molecular mechanism underlying the upregulation of chemokine receptors-mediated nociceptive sensation remains to be elucidated.

Previous studies have reported that GRK6 may phosphorylate distinct chemokine receptors in mediating different cellular functions. In this study, we sought to explore roles of GRK6 in DRGs and to determine the specific chemokine receptor signaling pathway mediated by GRK6 under neuropathic pain conditions. To that end, we investigated the temporal expression and cellular location of GRK6 in the DRGs in a well-established CCI model. We then tested the pain behaviors and measured the excitability of hind paw innervating DRG neurons after injection of GRK6 over-expression lentivirus. We showed GRK6 was downregulated following CCI and that overexpression of GRK6 attenuated the pain responses and suppressed the upregulation of CXCR2. Collectively, our findings represented a peripheral role of GRK6 in CCI model and supported a new mechanism underlying the activation of CXCR2 signal pathway in neuropathic pain.

Methods and materials

Induction of CCI-induced pain model

Experiments were performed on adult Sprague-Dawley (SD) rats (200 ± 20 g, male). Animals were housed under controlled conditions (24°C ± 2°C, 12:12-h alternating light–dark cycle) with free access to food and water. All experiments were approved by the Institutional Animal Care and Use Committee of Soochow University and were in accordance with the guidelines of the International Association for the Study of Pain. The surgical procedure was carried out aseptically under anesthetized with chloral hydrate (10% solution, ip). CCI was performed at the mid-thigh level of the right hind leg by loosely ligating the common sciatic nerve as described previously. In brief, proximal to the sciatic trifurcation, four ligatures (4.0 chromic gut) were loosely tied around the isolated sciatic nerve with a 1.0 to 1.5 mm interval between each of them. The sciatic nerves of Sham-operated rats were identically exposed and manipulated but no ligation was made. Skin wound was sutured with 7.0 nylon suture.

Pain behavior measurements

Male rats (CCI group, n = 8; Sham group, n = 8) were used for assessment of mechanical allodynia and thermal hyperalgesia of the hind paws 3 days before surgery and 3, 7, 14, 21 days after surgery by an investigator in a blinded manner. Mechanical allodynia was measured as changes in hind paw mechanical withdrawal thresholds (PWT) by using von Frey filaments (VFF) as previously described. Briefly, rats were placed in individual plastic boxes and allowed to acclimate for at least a half hour. A series of calibrated VFFs (0.55, 0.93, 1.61, 1.98, 2.74,
4.87, 7.37, 11.42, 15.76, and 20.30 g) were applied perpendicularly to the plantar surface of the hind paw with sufficient force to bend filaments for 1 to 2 s. A next greater force VFF was used in the presence of a response, and a next lower force VFF was employed in the absence of a response. The cut-off strength of VFF was set at 20.30 g to avoid unnecessary tissue damage during the tests. The modification of the “up-down” calculating method was applied to determine the value at which paw withdrawal occurred 50% of the time. Each trial was repeated three times at approximately 5-min intervals, and the average value was PWT.

Thermal hyperalgesia of the hind paw was measured by a well-established method previously. In brief, rats were placed on the clear glass surface of acrylic chambers and allowed to acclimatize for a half hour. A radiant heat source focused onto the plantar surface of the hind paw. The intensity of the thermal stimulus was adjusted to derive an approximately 10.0 s baseline of paw withdrawal latency (PWL) in normal animals. Measurements of PWL were determined by a timer that was started by activation of a heat source and stopped when the hind paw withdrawal was detected with a photodetector. A maximal cut-off time of 20 s was applied to prevent tissue damage during the heat tests. The mean PWL was obtained by averaging the latency of three measurements with a 10-min interval between consecutive tests.

Western blotting

Rats were sacrificed by an overdose of chloral hydrate. Lumbar DRGs (L4-L6) from the ipsilateral side were quickly dissected out and frozen in liquid nitrogen. Each sample was lysed and centrifuged at 12,000 r/min for 30 min at 4°C to collect the supernatant; 20 mg of protein was fractionated on 10% polyacrylamide gels (Bio-Rad, Hercules, CA, USA) and then transferred to polyvinyl difluoride (PVDF) membranes (Bio-Rad, USA) for 2 h at 200 mA. The membranes were blocked in TBS (50 mM Tris-Base, 133 mM NaCl, pH 7.4) containing a 5% dilution of non-fat milk powder for 2 h at room temperature (RT) and then incubated with polyclonal primary antibody for GRK6 (anti-rabbit, 1:200, Santa Cruz Biotechnology, USA), CXCR1 (anti-rabbit, 1:100, Santa Cruz Biotechnology, USA), CXCR2 (anti-rabbit, 1:50, Boster, P.R. China), CXCR4 (anti-rabbit, 1:100, Santa Cruz Biotechnology, USA), and specific marker proteins such as a rabbit polyclonal CGRP antibody (1:100, Chemicon), FITC-conjugated Bandeiraea simplicifolia BS-I isolecitin B4 (IB4, 5 μg/mL, Sigma), mouse monoclonal anti-GFAP (1:200, Sigma), β-tubulin (1:200, Millipore) overnight at 4°C. The following day, a mixture of secondary antibody with Alexa Fluor 488 and 355 were added and incubated for 2 to 3 h in a dark room at RT. Negative control (NC) was performed by omitting primary antibody. Sections were viewed with filter cubes appropriate for Alexa 355, 488, and DiI (rhodamine filter). The stained sections were viewed with a Leica fluorescence microscope (Germany). Images were captured and analyzed by Metaview software as described previously.

Cell retrograde labeling

DRG neurons innervating the hind paw were labeled by retrograde tracing using 1,1’dioleoyl 3, 3, 3’, tetramethylindocarbocyanine methanesulfonate (DiI; Invitrogen, Carlsbad, CA, USA), as described previously. One week later, lumbar L4-L6 DRGs from CCI or sham operation rats were dissected out for patch-clamp recordings of neuronal excitability or immunostaining studies.

Dissociation of DRG neurons and patch-clamp recordings

Changes in neuronal excitability were determined using whole-cell patch-clamp recording techniques as described previously. In brief, the ipsilateral L4-L6 DRGs were dissected out one week after DiI injection. Three DRGs were then transferred to an ice-old and oxygenated fresh dissecting solution containing collagenase D (1.8 to 2.0 mg/mL; Roche, Indianapolis, IN, USA).
USA) and trypsin (1.2 to 1.5 mg/mL; Sigma, St Louis, MO, USA) and incubated for 1.5 h at 34.5°C. The dissecting solution contains (in mmol/L) 130 NaCl, 5 KCl, 2 KH₂PO₄, 1.5 CaCl₂, 6 MgSO₄, 10 glucose, and 10 HEPES, pH = 7.2; osmolality = 305 mOsm. The ganglia were then transferred to 2 mL of the dissecting solution with DNase (0.5 mg/mL, Sigma, USA). A single cell suspension was subsequently obtained by repeated trituration through flame-polished glass pipettes. Cells were plated onto acid-cleaned glass coverslips. DiI-labeled neurons were identified by their fluorescence under a fluorescence microscope (Olympus IX71, Japan). Normal external solution contains (in mmol/L) 130 NaCl, 5 KCl, 2 KH₂PO₄, 2.5 CaCl₂, 1 MgCl₂, 10 HEPES, 10 glucose, with pH adjusted to 7.2 with NaOH; 295 to 300 mOsm. Patch-clamp pipettes had a resistance of 4 to 7 MΩ when filled with the pipette solution, which contains (in mmol/L) 140 potassium gluconate, 10 NaCl, 10 HEPES, 10 glucose, 5 EGTA, and 1 CaCl₂, pH = 7.25 adjusted with KOH; 292 mOsm. The resting membrane potential (RP) and action potentials (APs) were recorded under current-clamp configuration using an EPC10 patch-clamp amplifier (HEKA, Germany). Neurons with a RP more depolarized than −40 mV were excluded in the data analysis.

Drug application
SB225002 (purchased from Selleck, USA), a selective inhibitor of CXCR2, was freshly prepared in DMSO (Sigma). Seven days after CCI application, SB225002 was administered intrathecally at different doses (20, 40, and 60 μg in 10 μL DMSO) for the behavioral measurements. A guiding needle (18 G) was passed between the lumbar vertebrae 5 and 6 to enter the intrathecal space and the SB225002 solution was slowly injected.

Lentiviral vectors production and infection
The full-length of GRK6 was cloned from rat brain cDNA library and sub-cloned into pENTR™/D-TOPO vector. After recombined the enter clone pENTR™/D-TOPO GRK6 with the lentiviral destination vector (LR and BP) by the recombined enzymes, the recombined lentiviral destination vector and packaging plasmids (Shanghai Gene Chem Co. Ltd., P.R. China) were co-transfected 293FT cells to generate virus stocks of Lenti-GRK6 (LV-GRK6) or NC lentivirus (LV-NC) after 72 h. Estimated titers of the concentrated LV-NC/LV-GRK6 were 1.25 × 10⁸ transducing units per milliliter (TU/mL). Adult SD rats weighing 180 to 220 g were used. The animals were anesthetized by isoflurane (1-chloro-2, 3, 4-trifluoroethyl ether, AErrane) with oxygen. Operations were performed using an operating microscope under aseptic conditions. The sciatic nerves were exposed in the mid-gluteal region through a gluteal muscle-splitting incision. A 27-G needle was inserted longitudinally into the nerve and 4 μL volume of LV-NC/LV-GRK6 was injected slowly using a micromanipulator. The nerves were anatomically repositioned, and the skin was closed with 7.0 nylon sutures.

Co-immunoprecipitation (Co-IP)
Each sample was lysed and centrifuged at 12,000 r/min for 30 min at 4°C to collect the supernatant. The concentration of protein in the supernatant was determined by the Bradford method using BSA as standard (BioRad); 500 μg extract was incubated with either 5 μg anti-GRK6 antibody (anti-mouse, 1:200, Santa Cruz Biotechnology, USA) or pre-immune IgG in 500 μL of Co-IP buffer (Active motif) at 4°C overnight with rotation. The immunoprecipitates were isolated on Protein A beads and separated by 10% SDS-PAGE followed by transferring to PVDF membrane. The membrane was probed with antibodies against GRK6 and CXCR2 (anti-rabbit, 1:100, Boster, P.R. China).

Quantification and statistics
All data are expressed as means±SEM. Statistical testing was carried out using a stepwise procedure depending upon the number of groups being compared. Normality was first examined for all data before analysis. When only two means were involved in a comparison, a two-tailed t test with unequal variances was used. When more than two means were involved, a one-way analysis of variance (ANOVA) or Friedman ANOVA was first carried out to obtain a global test of the null hypothesis. If the global p value for the test of the null hypothesis was <.05, post hoc comparisons between the different groups using Mann–Whitney test or Dunn’s post hoc test were performed. A comparison was considered statistically significant when a p value was <.05.

Results
CCI induces persistent neuropathic pain and downregulates GRK6 expression in DRGs
CCI significantly produced mechanical allodynia and thermal sensitivity of the injured hind paw compared with the Sham-operated rats. In CCI group, a persistent decreased mechanical paw withdrawal threshold (PWT) on the ipsilateral side was observed from 3 days through 21 days after surgery, and the maximal mechanical allodynia was shown at seven days (Figure 1(a), n = 8 for each group, *p < .05 vs. Sham, Mann–Whitney test...
following Friedman ANOVA). Similarly, withdrawal latencies of the affected hind paw to radiant heat were significantly reduced from post-operative day 3 to day 21 compared with those of the Sham group (Figure 1(b), \( n = 8 \) for each group, \( *p < .05 \) vs. Sham, Mann–Whitney test following Friedman ANOVA). To investigate the temporal expression of GRK6 in L4-L6 DRGs following CCI, DRGs from ipsilateral side at 3, 7, 21 days were analyzed by Western blot assay. GRK6 protein expression was significant reduced from day 3 to day 21 after surgery, and the lowest level appeared at day 7 (Figure 1(c), \( n = 3 \) for each group, \( *p < .05 \) vs. Sham). In addition, we determined the cellular location of GRK6 expression in the DRGs using immunofluorescence staining. Double staining showed that GRK6-like immunoreactivities were mostly in neurons marked with \( \beta \)-tubulin and not expressed in glial cells labeled with GFAP. Co-location of GRK6 with IB4 and CGRP demonstrated that GRK6 expressed in both non-peptide and peptide containing DRG neurons with unmyelinated fibers (Figure 1(d)).

\textbf{Overexpression of GRK6 attenuates the mechanical allodynia and heat hyperalgesia}

To further explore the role of GRK6 in the peripheral regulation of neuropathic pain induced by CCI, we next determined whether administration of GRK6-LV suppressed the mechanical hyperalgesia and heat hyperalgesia. Figure 2(a) showed that transgene expression could be achieved in the corresponding DRG after injection of lentiviral carrying the green fluorescent protein (LV-GFP) into the sciatic nerves (Figure 2(a), right). The GRK6-LV efficiency in DRG was examined by Western blot assay (Figure 2(b)). Before LV administration, PWT and PWL in three groups (CCI, NC-LV, and GRK6-LV) had no significant difference (Figure 2(c) and (d), PRE). However, GRK6 overexpression by lentiviral injection on sciatic nerve greatly enhanced PWT (Figure 2(c), \( *p < .05 \) vs. NC-LV, Mann–Whitney test following Friedman ANOVA) and PWL (Figure 2(d), \( *p < .05 \) vs. NC-LV, Mann–Whitney test following Friedman ANOVA) in rats with CCI.

\begin{figure}
\centering
\includegraphics[width=\textwidth]{figure1.png}
\caption{Enhanced neuropathic pain and decreased expression of GRK6 in CCI rats. (a) CCI induces a significant decrease in PWT from 3 days to 21 days after surgery in the ipsilateral side. \( *p < .05 \), compared with Sham group. (b) The development of heat hyperalgesia from 3 days to 21 days was induced by CCI in the ipsilateral side. \( *p < .05 \), compared with Sham group. (c) Expression of GRK6 protein in DRGs was decreased from 3 days to 21 days after surgery in the ipsilateral side with the lowest level seven days after CCI. \( *p < .05 \), compared with Sham group. (d) GRK6 mainly expressed in neurons co-localized with \( \beta \)-tubulin, IB4, and CGRP in DRGs, but not in glial cells stained with GFAP. Bar = 75 \( \mu \)m.}
\end{figure}
CCI enhances the excitability of DRG neurons

To determine whether primary sensory afferents are involved in the development of hypersensitivity in CCI rats, we measured the excitability of hind paw innervating DRG neurons from Sham and CCI rats. Hind paw innervating DRG neurons were labeled by the fluorescent dye DiI injected into the right hind paw at five different points (Figure 3(a)). The small- and medium-sized DRG neurons were used in this study because they are the primary sensory neurons responsible for pain sensation. Under current-clamp conditions, a total of 22 cells were recorded. RPs were $48.8 \pm 1.0$ mV ($n = 11$) and $42.2 \pm 0.5$ mV ($n = 11$) for hind paw innervating DRG neurons isolated from Sham and CCI rats, respectively. CCI significantly depolarized RP (Figure 3(b); *$p < .05$, compared with Sham, Mann–Whitney test). The AP thresholds were $26.9 \pm 1.0$ mV ($n = 11$) and $31.0 \pm 1.7$ mV ($n = 11$) for Sham and CCI rats, respectively. CCI remarkably hyperpolarized the AP threshold (Figure 3(c); *$p < .01$, compared with Sham, Mann–Whitney test). The rheobase measurements were $77.3 \pm 10.5$ pA ($n = 11$) and $25.9 \pm 6.0$ pA ($n = 11$) for Sham and CCI rats, respectively. CCI also markedly reduced rheobase (Figure 3(d); *$p < .05$, compared with Sham, two-sample $t$ test). In addition, CCI resulted in a dramatic increase in the numbers of APs evoked by 100 and 300 pA ramp current stimulation (Figure 3(e) to (h); *$p < .05$, compared with Sham, two-sample $t$ test). The numbers of APs evoked by 100 pA ramp current stimulation were $2.8 \pm 1.0$ ($n = 11$) and $9.6 \pm 1.3$ ($n = 11$) for Sham and CCI rats, respectively. The numbers of AP evoked by 300 pA ramp current stimulation were $8.5 \pm 1.1$ ($n = 11$) and $15.0 \pm 2.0$ ($n = 11$) for Sham and CCI rats, respectively. CCI significantly enhanced the numbers of APs in response to ramp current stimulation.

Overexpression of GRK6 reverses CCI-induced hyperexcitability of DRG neurons

Because GRK6 overexpression attenuates the mechanical allodynia and heat hyperalgesia in CCI rats, we next investigated whether GRK6 overexpression affects the excitability of hind paw innervating DRG neurons of CCI rats. Under current-clamp conditions, a total of 12 cells were recorded from three CCI rats treated with GRK6-LV injection and a total of 12 cells were from three CCI rats treated with NC-LV. Only GRK6-LV-infected (green, stained with GFP) hind paw innervating
DRG neurons (red, Dil fluorescence) were measured in the present study (Figure 4(A)). RPs were $-43.9 \pm 1.0 \text{mV} \ (n=12)$ and $-48.2 \pm 0.9 \text{mV} \ (n=12)$ for hind paw innervating DRG neurons isolated from NC-LV and GRK6-LV groups, respectively. Therefore, GRK6 overexpression significantly hyperpolarized the resting membrane potential (RP) of hind paw innervating DRG neurons. $^*p < .05$ vs. Sham. (c) CCI notably hyperpolarized the action potential (AP) threshold. $^*p < .05$ vs. Sham. (d) CCI also markedly decreased rheobase. $^*p < .05$ vs. Sham. (e, g) Examples of APs by 100 and 300 pA ramp current injection from Sham and CCI rats. (f, h) Bar graph showed a significant increase in numbers of APs evoked by 100 and 300 pA ramp current stimulation in CCI rats. $^*p < .05$ vs. Sham. RP: resting membrane potential; AP: action potential; CCI: chronic constriction injury.

Figure 3. Enhanced excitability of DRG neurons in CCI rats. (a) Bright-field (right) and DiI fluorescence (left) images of acutely dissociated DRG neurons. A hind paw innervating DRG neuron is shown in red (arrow). Bar = 50 μm. (b) CCI significantly depolarized the resting membrane potential (RP) of hind paw innervating DRG neurons. $^*p < .05$ vs. Sham. (c) CCI notably hyperpolarized the action potential (AP) threshold. $^*p < .05$ vs. Sham. (d) CCI also markedly decreased rheobase. $^*p < .05$ vs. Sham. (e, g) Examples of APs by 100 and 300 pA ramp current injection from Sham and CCI rats. (f, h) Bar graph showed a significant increase in numbers of APs evoked by 100 and 300 pA ramp current stimulation in CCI rats. $^*p < .05$ vs. Sham. RP: resting membrane potential; AP: action potential; CCI: chronic constriction injury.
and GRK6-LV groups, respectively. GRK6 overexpression significantly decreased the numbers of APs in response to ramp current stimulation.

**Overexpression of GRK6 reduces CXCR2 upregulation**

CXC family chemokines have been reported to play a vital role in pain regulation via respective receptors. To determine whether the chemokine receptors are regulated by GRK6 in neuropathic pain, we first detected the change in CXCR1, CXCR2, and CXCR4 protein levels at seven days after CCI application. We selected this time point to perform experiments because both PWT and PWL were at the lowest point on the time-response curve (Figure 1(a) and (b)). As shown in Figure 5(a) to (c), the protein expression of CXCR1, CXCR2, and CXCR4 were all increased markedly in CCI rats when compared with Sham group (*p < .05, two-sample t test). We then investigated whether the upregulation of CXCR1, CXCR2, and CXCR4 was mediated by GRK6. GRK6-LV was used in this study as described above. GRK6 overexpression significantly reversed the

*Figure 4.* Reversal of hyperexcitability of DRG neurons in CCI rats by GRK6 overexpression. (A) Bright-field (a), GRK6 LV-GFP (b), Dil fluorescence (c), and merge of GFP and Dil fluorescence (d) images of acutely dissociated DRG neurons. A hind paw innervating DRG neuron infected by GRK-LV is indicated by arrow. Bar = 50 μm. (B) GRK6 overexpression significantly hyperpolarized the RP of hind paw innervating DRG neurons. *p < .05 vs. NC-LV. (C) GRK6 overexpression notably depolarized the AP threshold (*p < .05 vs. NC-LV). (D) GRK6 overexpression also markedly increased rheobase. *p < .05 vs. NC-LV. (E, G) Examples of APs by 100 and 300 pA ramp current injection from NC-LV and GRK6-LV-infected DRG neurons. (F, H) Bar graph showed a significant decrease in numbers of APs evoked by 100 and 300 pA ramp current stimulation by GRK6 overexpression. *p < .05 vs. NC-LV. RP: resting membrane potential; AP: action potential; NC-LV: negative control lentivirus.
CXCR2 upregulation (*p < .05, two-sample t test, Figure 5(e)) but did not alter the expression of CXCR1 (Figure 5(d), p > .05, two–sample t test) and CXCR4 (Figure 5(f), p > .05, two-sample t test).

**CXCR2 is associated with GRK6 and CXCR2 inhibitor attenuates CCI-induced neuropathic pain**

To further confirm the role of GRK6 on CXCR2 expression in CCI model, we then examined the time course of CXCR2 protein expression and correlation between the expression of CXCR2 and GRK6 of DRGs after CCI. Western blot analysis showed a clear increase in CXCR2 expression persisted from 3 days to 21 days following CCI (Figure 6(a)). As expected, correlation analysis showed that the alternations of CXCR2 and GRK6 following CCI were in a negative correlativity (Figure 6(b), r = 0.824, p = .042). In addition, Co-IP showed an interaction of GRK6 and CXCR2 in DRGs of CCI rats (Figure 6(e)). Immunofluorescence analysis demonstrated that CXCR2 was co-expressed in GRK6 positive DRG neurons (Figure 6(d)). To further verify the function of CXCR2 in neuropathic pain of rats with CCI, we showed that intrathecal injection of SB225002, a selective antagonist of CXCR2, significantly suppressed mechanical allodynia (Figure 6(e), *p < .05 vs. NS, Mann–Whitney test following Friedman ANOVA) and heat hyperalgesia (Figure 6(f), *p < .05 vs. NS, Mann–Whitney test following Friedman ANOVA) in CCI rats.

**Discussion**

The present study has shown that GRK6 plays a pivotal role in the maintenance of peripheral sensitization in neuropathic pain via regulation of CXCR2 signaling. Our data showed that CCI produced mechanical allodynia and thermal hyperalgesia accompanied with a significant reduction in GRK6 protein expression, which are located in DRG neurons. Overexpression of GRK6 by lentiviral injection into sciatic nerve significantly attenuated CCI-induced pain responses and markedly reversed hyperexcitability of DRG neurons innervating the sensitized plantar. Furthermore, we demonstrated here for the first time that overexpression of GRK6 suppressed CXCR2 expression in rat DRGs. These data suggest that overexpression of GRK6 attenuates mechanical allodynia and thermal hyperalgesia most likely through suppression of CXCR2 expression in rat DRGs.

As reported previously, decreased GRK6 levels led to a markedly decrease in pain threshold.17,18
Female GRK6−/− mice presented enhanced visceral hyperalgesia post-colitis. Mechanical allodynia and thermal hyperalgesia induced by intraplantar injection of inflammatory mediators are also pronounced and prolonged in GRK6−/− mice. Our study showed CCI-induced downregulation of GRK6 protein expression in ipsilateral DRGs, which is in line with the declined GRK6 mRNA expression in ipsilateral DRGs reported recently in another neuropathic pain model of L5 nerve transection.
Attenuation of pain responses and reversal of the excitability of sensory neurons by GRK6 overexpression in DRGs indicated the peripheral role of GRK6 in neuropathic pain, which was consistent with our previous report about the expression and role of GRK6 in spinal cord dorsal horn of CCI rats.19

The mechanism underlying negative regulation of GRK6 on pain hypersensitivity is largely unknown. GRK6, as a ubiquitously expressed member of the GRK family, has been described to experience a marked change and play a critical role in inflammatory disease in humans or animal models. Profound downregulation of GRK6 expressions have been reported in rheumatoid arthritis or multiple sclerosis.11,12 Interestingly, the data of the previously published pain-related behavior tests in GRK6-/- and WT animals showed that at baseline there was no difference in pain threshold between these two groups. This indicated that low GRK6 level per se is not sufficient to decrease pain threshold except participation of an inflammatory stimulus. Therefore, we speculated that the role of decreased GRK6 in DRGs might be associated with the neuroinflammation. There is growing body of evidence that chemokines and their receptors play a role in inducing and regulating neuronal excitability.30 APs evoked by the injection of different sizes of current ramps. CXCL1, the primary ligand of CXCR2, have been revealed modulating neuronal excitability of DRG neurons, including intracellular Ca2+, inositol trisphosphate, MAP kinases, and CREB, thus leading to synaptic plasticity, as a pivotal mechanism for chronic pain, also occurs at different levels of the central nervous system. Nerve injury triggers long-term plastic changes along sensory pathways, from the peripheral sensory terminals to the spinal cord dorsal horn,41 amygdale,42 and anterior cingulate cortex.43-45

In addition, increasing literature implicated a role of
GRK6 in central sensitization of neuropathic pain. GRK6 has been reported expressed in neurons of spinal cord,19 cortex,46 and hippocampus.47 Whether GRK6 is involved in the maintenance of pain-related long-term synaptic plasticity changes in spinal and/or supraspinal synapses needs further exploration. It is worth to be mentioned here, that the method of lentivirus injection through sciatic nerve, different from traditional intrathecal injection, has profound advantage in demonstrating the peripheral mechanism of neuropathic pain. We showed that transgene expression was successfully achieved in the sciatic nerves and the corresponding DRG but not in other irrelative DRGs and spinal cord. It is clear and definite to illustrate the peripheral role of the transgene in pain modulation. In addition, this injection is controllable and convenient to be conducted with negligible nerve damage compared with nerve injury of neuropathic pain model. Future experiments are warranted to optimize the approaches for LV delivery into DRGs.

In conclusion, to the best of our knowledge, we provide the first demonstration that GRK6 plays a pivotal role in the maintenance of peripheral sensitization in neuropathic pain via regulation of CXCR2 signaling pathway. The present results and future studies might identify a potential therapeutic target for the treatment of the intractable neuropathic pain.

Author Contributions
YZ researched, analyzed data, and wrote the manuscript. RJL researched, analyzed data, and wrote the manuscript. XL researched and analyzed data. HYZ researched and analyzed data. ZJ analyzed data. XM analyzed data and wrote the manuscript. GYX designed and supervised the experiments, and edited the manuscript. All authors read and approved the final manuscript.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by grants from National Natural Science Foundation of China (81230024 and 81471137) and from the Priority Academic Program Development of Jiangsu Higher Education Institutions of China. This project is also subject to the Second-Affiliated Hospital of Soochow University Preponderant Clinic Discipline Group Project Funding (XKQ2015008). The all funders had no role in the experimental designs, data collection and analyses, decision to publish, or preparation of the manuscript.

References
1. White FA, Jung H and Miller RJ. Chemokines and the pathophysiology of neuropathic pain. Proc Natl Acad Sci U S A 2007; 104: 20151–20158.
2. Abbadi C, Bhangoo S, De Koninck Y, et al. Chemokines and pain mechanisms. Brain Rev 2009; 60: 125–134.
3. Ji RR, Gereau RWt, Malcangio M, et al. MAP kinase and pain. Brain Rev 2009; 60: 135–148.
4. Geppetti P, Veldhuis NA, Lieu T, et al. G protein-coupled receptors: dynamic machines for signaling pain and itch. Neuron 2015; 88: 635–649.
5. Waxman SG and Zamponi GW. Regulating excitability of peripheral afferents: emerging ion channel targets. Nat Neurosci 2014; 17: 153–163.
6. Stone LS and Molliver DC. In search of analgesia: emerging roles of GPCRs in pain. Mol Inter 2009; 9: 234–251.
7. Ribas C, Penela P, Murga C, et al. The G protein-coupled receptor kinase (GRK) interactome: role of GRKs in GPCR regulation and signaling. Biochim Biophys Acta 2007; 1768: 913–922.
8. Premont RT and Gainetdinov RR. Physiological roles of G protein-coupled receptor kinases and arrests. Annu Rev Physiol 2007; 69: 511–534.
9. Ruiz-Gomez A, Mellstrom B, Tornero D, et al. G protein-coupled receptor kinase 2-mediated phosphorylation of downstream regulatory element antagonist modulator regulates membrane trafficking of Kv4.2 potassium channel. J Biol Chem 2007; 282: 1205–1215.
10. Hall RA, Spurney RF, Premont RT, et al. G protein-coupled receptor kinase 6A phosphorylates the Na(+)/H(+) exchanger regulatory factor via a PDZ domain-mediated interaction. J Biol Chem 1999; 274: 24328–24334.
11. Giorelli M, Livrea P and Trojano M. Post-receptorial mechanisms underlie functional disregulation of beta2-adrenergic receptors in lymphocytes from multiple sclerosis patients. J Neuroimmun 2004; 155: 143–149.
12. Lombardi MS, Kavelaars A, Cobelens PM, et al. Adjuvant arthritis induces down-regulation of G protein-coupled receptor kinases in the immune system. J Immunol 2001; 166: 1635–1640.
13. Aiyar N, Disa J, Kang K, et al. Involvement of G protein-coupled receptor kinase-6 in desensitization of CGRP receptors. Eur J Pharmacol 2000; 403: 1–7.
14. Tarrant TK, Ramspad RS, Esserman D, et al. Granulocyte chemotaxis and disease expression are differentially regulated by GRK subtype in an acute inflammatory arthritis model (K/BxN). Clin Immunol 2008; 129: 115–122.
15. Yuan L, Zhang H, Liu J, et al. Growth factor receptor-Src-mediated suppression of GRK6 dysregulates CXCR4 signaling and promotes medulloblastoma migration. Mol Cancer 2013; 12: 18.
16. Murga C and Mayor F, Jr. GRK6, a gatekeeper of visceral hyperalgesia. Brain Behav Immun 2009; 23: 16–17.
17. Eijkelkamp N, Heijnen CJ, Elenbruch S, et al. G protein-coupled receptor kinase 6 controls post-inflammatory visceral hyperalgesia. Brain Behav Immun 2009; 23: 18–26.
18. Eijkelkamp N, Heijnen CJ, Carbajal AG, et al. G protein-coupled receptor kinase 6 acts as a critical regulator of cytokine-induced hyperalgesia by promoting phosphatidylinositol 3-kinase and inhibiting p38 signaling. *Mol Med* 2012; 18: 556–564.

19. Zhou Y, Huang X, Wu H, et al. Decreased expression and role of GRK6 in spinal cord of rats after chronic constriction injury. *Neurochem Res* 2013; 38: 2168–2179.

20. White FA and Wilson NM. Chemokines as pain mediators and modulators. *Curr Opin Anaesthesiol* 2008; 21: 580–585.

21. Ransohoff RM, Liu L and Cardona AE. Chemokines and chemokine receptors: multipurpose players in neuroinflammation. *Int Rev Neurobiol* 2007; 82: 187–204.

22. Charo IF and Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. *N Engl J Med* 2006; 354: 610–621.

23. Cao DL, Zhang ZJ, Xie RG, et al. Chemokine CXCL1 enhances inflammatory pain and increases NMDA receptor activity and COX-2 expression in spinal cord neurons via activation of CXCR2. *Exp Neurol* 2014; 261: 328–336.

24. Kim SJ, Park SM, Cho YW, et al. Changes in expression of mRNA for interleukin-8 and effects of interleukin-8 receptor inhibitor in the spinal dorsal horn in a rat model of lumbar disc herniation. *Spine (Phila Pa 1976)* 2011; 36: 2139–2146.

25. Luo X, Wang X, Xia Z, et al. CXCL12/CXCR4 axis: an emerging neuromodulator in pathological pain. *Rev Neurosci* 2016; 27: 83–92.

26. Zhang ZJ, Cao DL, Zhang X, et al. Chemokine contribution to neuropathic pain: respective induction of CXCL1 and CXCR2 in spinal cord astrocytes and neurons. *Pain* 2013; 154: 2185–2197.

27. Lopes AH, Brandolini L, Aramini A, et al. DF2755A, a novel non-competitive allosteric inhibitor of CXCR1/2, reduces inflammatory and post-operative pain. *Pharmacol Res* 2015; 103: 69–79.

28. Yang F, Sun W, Yang Y, et al. SDF1-CXCR4 signaling contributes to persistent pain and hypersensitivity via regulating excitability of primary nociceptive neurons: involvement of ERK-dependent Nav1.8 up-regulation. *J Neuroinflammation* 2015; 12: 219.

29. McCormick PJ, Segarra M, Gasperini P, et al. Impaired recruitment of Grk6 and beta-arrestin 2 causes delayed internalization and desensitization of a WHIM syndrome-associated CXCR4 receptor mutant. *PLoS One* 2009; 4: e8102.

30. Raghuvanshi SK, Su Y, Singh V, et al. The chemokine receptors CXCR1 and CXCR2 couple to distinct G protein-coupled receptor kinases to mediate and regulate leukocyte functions. *J Immunol* 2012; 189: 2824–2832.

31. Bennett GJ and Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. *Pain* 1988; 33: 87–107.

32. Chaplan SR, Bach FW, Pogrel JW, et al. Quantitative assessment of tactile allodynia in the rat paw. *J Neurosci Methods* 1994; 53: 55–63.

33. Hargreaves K, Dubner R, Brown F, et al. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. *Pain* 1988; 32: 77–88.

34. Zhang HH, Hu J, Zhou YL, et al. Promoted interaction of nuclear factor-kappaB with demethylated cystathionine-beta-synthetase gene contributes to gastric hypersensitivity in diabetic rats. *J Neurosci* 2013; 33: 9028–9038.

35. Hunt SP and Mantyh PW. The molecular dynamics of pain control. *Nat Rev Neurosci* 2001; 2: 83–91.

36. Busillo JM, Armando S, Sengupta R, et al. Site-specific phosphorylation of CXCR4 is dynamically regulated by multiple kinases and results in differential modulation of CXCR4 signaling. *J Biol Chem* 2010; 285: 7805–7817.

37. Wang JG, Strong JA, Xie W, et al. The chemokine CXCL1/growth related oncogene increases sodium currents and neuronal excitability in small diameter sensory neurons. *Mol Pain* 2008; 4: 38.

38. Yang RH, Strong JA and Zhang JM. NF-kappaB mediated enhancement of potassium currents by the chemokine CXCL1/growth related oncogene in small diameter rat sensory neurons. *Mol Pain* 2009; 5: 26.

39. Dong F, Du YR, Xie W, et al. Increased function of the TRPV1 channel in small sensory neurons after local inflammation or in vitro exposure to the pro-inflammatory cytokine GRO/KC. *Neurosci Bull* 2012; 28: 155–164.

40. Ragozzino D. CXC chemokine receptors in the central nervous system: role in cerebellar neuromodulation and development. *J Neurovirol* 2002; 8: 559–572.

41. Ikeda H, Stark J, Fischer H, et al. Synaptic amplifier of inflammatory pain in the spinal dorsal horn. *Science* 2006; 312: 1659–1662.

42. Fu Y and Neugebauer V. Differential mechanisms of CRF1 and CRF2 receptor functions in the amygdala in pain-related synaptic facilitation and behavior. *J Neurosci* 2008; 28: 3861–3876.

43. Li XY, Ko HG, Chen T, et al. Alleviating neuropathic pain hypersensitivity by inhibiting PKMζeta in the anterior cingulate cortex. *Science* 2010; 330: 1400–1404.

44. Liu SB, Zhang MM, Cheng LF, et al. Long-term upregulation of cortical glutamatergic AMPA receptors in a mouse model of chronic visceral pain. *Mol Brain* 2015; 8: 76.

45. Koga K, Descazi G, Chen T, et al. Coexistence of two forms of LTP in ACC provides a synaptic mechanism for the interactions between anxiety and chronic pain. *Neuron* 2015; 85: 377–389.

46. Bychkov ER, Ahmed MR, Gurevich VV, et al. Reduced expression of G protein-coupled receptor kinases in schizophrenia but not in schizoaffective disorder. *Neuropsychopharmacology* 2011; 44: 248–258.

47. Willets JM, Nash MS, Challiss RA, et al. Imaging of muscarinic acetylcholine receptor signaling in hippocampal neurons: evidence for phosphorylation-dependent and -independent regulation by G-protein-coupled receptor kinases. *J Neurosci* 2004; 24: 4157–4162.